Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Non Operating Income (2022 - 2025)

Dianthus Therapeutics (DNTH) has 4 years of Non Operating Income data on record, last reported at $10.7 million in Q3 2025.

  • For Q3 2025, Non Operating Income fell 21.46% year-over-year to $10.7 million; the TTM value through Sep 2025 reached $14.0 million, down 8.99%, while the annual FY2024 figure was $16.9 million, 28258.33% up from the prior year.
  • Non Operating Income reached $10.7 million in Q3 2025 per DNTH's latest filing, up from -$3.9 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $13.6 million in Q3 2024 and bottomed at -$3.9 million in Q2 2025.
  • Average Non Operating Income over 4 years is $2.6 million, with a median of $816000.0 recorded in 2023.
  • Peak YoY movement for Non Operating Income: plummeted 5216.28% in 2023, then surged 1266.77% in 2024.
  • A 4-year view of Non Operating Income shows it stood at -$43000.0 in 2022, then tumbled by 5216.28% to -$2.3 million in 2023, then skyrocketed by 252.06% to $3.5 million in 2024, then soared by 207.59% to $10.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $10.7 million in Q3 2025, -$3.9 million in Q2 2025, and $3.7 million in Q1 2025.